Limiting neurodegeneration in ALS: A phosphatase paves the way
Neuron · 2026-06 · 114 (12) · 2073-2075
DOI: 10.1016/j.neuron.2026.04.030 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuron, 2026-06. Verfasst von Elena I Rugarli und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Genetics, University of Cologne, Cologne, Germany; Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases…. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Nerve Degeneration, Phosphoric Monoester Hydrolases. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
Zheng et al. identify phosphatase PGAM5 as a novel promising target for the treatment of different amyotrophic lateral sclerosis subtypes. PGAM5 dephosphorylates and activates the stress-regulated mitochondrial peptidase OMA1, which elicits a maladaptive mitochondrial integrated stress response in motor neurons.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute for Genetics, University of Cologne, Cologne, Germany; Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.
- Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany; Max-Planck-Institute for Biology of Ageing, Cologne, Germany. Electronic address: tl…
Zitieren
APA
Rugarli, E. I., & Langer, T. (2026). Limiting neurodegeneration in ALS: A phosphatase paves the way. Neuron, 114(12), 2073-2075. https://doi.org/10.1016/j.neuron.2026.04.030
Vancouver
Rugarli EI, Langer T. Limiting neurodegeneration in ALS: A phosphatase paves the way. Neuron. 2026;114(12):2073-2075. doi:10.1016/j.neuron.2026.04.030
BibTeX
@article{Rugarli2026,
author = {Rugarli, Elena I and Langer, Thomas},
title = {Limiting neurodegeneration in ALS: A phosphatase paves the way},
journal = {Neuron},
year = {2026},
volume = {114},
number = {12},
pages = {2073--2075},
doi = {10.1016/j.neuron.2026.04.030}
}
EUVIMED